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ABSTRACT 
Ting Wang 
EFFECTS OF TRADITIONAL CHINESE MEDICINAL HERBAL EXTRACTS ON 
HIV-1 REPLICATION  
 
 
Background: The current treatment for HIV/AIDS is called highly active antiretroviral 
therapy (HAART) and is a combination of anti-HIV reverse transcriptase inhibitors and 
protease inhibitors.  HAART is capable of suppressing HIV replication and subsequently 
improving the patients’ survival.  However, the issues associated with use of HARRT 
such as the high cost, severe side-effects, and drug resistance have called for development 
of alternative anti-HIV therapeutic strategies.  In this study, we screened several 
traditional Chinese medicinal herbal extracts for their anti-HIV activities and determined 
their anti-HIV mechanisms.  
 
Methods: Nine traditional Chinese medicinal (TCM) herbal plants and their respective 
parts derived from Hainan Island, China were extracted using a series of organic solvents, 
vacuum dried, and dissolved in dimethyl sulfoxide.  Initial anti-HIV activity and 
cytotoxicity of these extracts were evaluated in HIV-infected human CD4+ T 
lymphocytes Jurkat.  Extracts of higher anti-HIV activities and lower cytotoxicity were 
selected from the initial screening, and further examined for their effects on HIV-1 entry, 
post-entry, reverse transcriptase, gene transcription and expression using combined 
virology, cell biology and biochemistry techniques.  
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Results: Four extracts derived from two different herbal plants completely blocked HIV-1 
replication and showed little cytotoxicity at a concentration of 10 g/ml.  None of these 
four extracts had any inhibitory effects on HIV-1 long terminal repeat promoter.  Two of 
them exhibited direct inhibitory activity against HIV-1 reverse transcriptase (RT).  All 
four extracts showed significant blocking of HIV-1 entry into target cells. 
 
Conclusions: These results demonstrated that four TCM extracts were capable of 
preventing HIV-1 infection and replication by blocking viral entry and/or directly 
inhibiting the RT activity.  These results suggest the possibility of developing these 
extracts as potential anti-HIV therapeutic agents.  
 
        
 
                        
 
                                                                                         Johnny J. He, Ph.D. Committee Chair 
  
vi 
 
TABLE OF CONTENTS 
INTRODUCTION............................................................................................................. 1 
 
 
METHODS AND MATERIALS ...................................................................................... 9 
Preparation of plant extracts ............................................................................................... 9 
Cells, HIV-1 HXB2/YU-2 viruses and chemicals .............................................................. 9 
Preparation and infection of HIV-1 pseudotyped viruses ................................................. 10 
HIV replication assay .........................................................................................................11 
Cytotoxicity assay ............................................................................................................. 12 
Flow cytometry analysis ................................................................................................... 12 
Data analysis .................................................................................................................... 12 
 
 
RESULTS ......................................................................................................................... 13 
Anti-HIV activity of the extracts of traditional Chinese medicinal herbal plants ............ 13 
Cytotoxicity of the extracts ............................................................................................... 14 
Dose-dependent inhibition of HIV-1 replication by these extracts ................................... 14 
Block of HIV-1 entry by these extracts ............................................................................. 15 
No effects of the extracts on HIV-1 infectivity ................................................................. 16 
vii 
 
No effects of the extracts on HIV-1 post-entry ................................................................. 16 
Inhibition of HIV-1 RT activity by extract of AAP-leaves and AAP-stems ..................... 17 
No inhibition of HIV-1 LTR promoter activity by the extracts......................................... 17 
 
 
DISCUSSIONS ................................................................................................................ 18 
 
 
REFERENCES ................................................................................................................ 42 
 
CURRICULUM VITAE 
viii 
 
LIST OF ABBREVIATIONS 
AAP                                 Annonaceae, Artabotrys pilosus  
ADR                                Annonaceae, Dasymaschalon rostratum  
AOH                                Annonaceae, Oncodostigma hainanense 
TCM                                traditional Chinese medicine 
HIV-Luc                          a HIV-1-based reporter virus containing inactive nef and env  
                                         genes and having the luciferase (Luc) gene inserted at the 5'  
                                         end nef gene 
HXB2-env                       envelope from HIV-1 isolate HXB2 
YU-2-env                        envelope from HIV-1 isolate YU-2 
VSV-G                             vascular stomatitis virus envelope glycoprotein 
RT                                    reverse transcriptase 
DMSO                             dimethyl sulfoxide 
AZT                                 azidothymidine  
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INTRODUCTION 
HIV/AIDS epidemics 
Acquired immune deficiency syndrome (AIDS) is caused by infection of human 
immunodeficiency virus type 1 (HIV-1) and is one of the most destructive pandemics [1].  
It has killed more than 25 million people since it was first diagnosed in 1981. Despite 
improved access to antiretroviral treatment and improved care in many regions of the 
world, the AIDS pandemic claimed an estimated 2.8 million (between 2.4 and 3.3 million) 
lives in 2005, of which more than half a million (570,000) were children [2, 3]. Sub-
Saharan Africa is the worst-affected region and has an estimated 21.6 to 27.4 million 
people currently living with HIV [4, 5]. The epidemic is spreading most rapidly in 
Eastern Europe and central Asia, where the number of people living with HIV increased 
67% between 2001 and 2008 [6, 7]. 
 
Based on the epidemic data in 2008, about half of the 31.3 million HIV/AIDS population 
are women and about 98 percent of these infected women are in developing countries [8].  
These figures suggest that women had a greater risk of acquiring HIV through 
heterosexual intercourse.  Studies have shown that women are twice more likely to 
become infected with HIV through unprotected heterosexual intercourse than men [9].  
There are a large number of HIV-infected women and women with AIDS.  As a result of 
vertical transmission from HIV/AIDS mothers to their infants during pregnancy, birth or 
breastfeeding, more and more children are living and affected by HIV/AIDS.  In Africa, 
one in every three newborn children is infected with HIV and dies before the age of one, 
and most of these infected children have died before they are five years old. 
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HIV transmissions and symptoms 
HIV can be transmitted via bodily fluids, such as blood, semen, vaginal fluid, pre-
ejaculate, or breast milk.  The virus is presented in the form of both free viruses and 
virus-infected immune cells.  HIV is a lentivirus and mainly infects dendritic cells, CD4+ 
T lymphocytes, and monocytes/macrophages in the human immune system [10].  
Infection with HIV-1 is associated with a decrease in CD4
+
 T cell count and an increase 
in viral load.  HIV infection can be divided into four different stages based on the 
patient’s CD4+ T cell count, and the viral load of HIV in the blood: primary incubation, 
which lasts 1-2 weeks; acute HIV vermin with virus dissemination into lymphoid organs 
[11]; clinical latency from several weeks up to 20 years; AIDS at which stage CD4+ T 
lymphocyte counts drop under 200 cells/mm
3
.  
 
 
Classification of HIV 
There are two known HIV species: HIV-1 and HIV-2.  HIV-1 was first discovered in 
1981 and used to be named as LAV or HTLV-III [12].  Compared to HIV-2, HIV-1 is 
more virulent, more infectious and constitutes the majority of HIV infections globally.  
HIV-2 is largely found in West Africa, but it has the relatively lower capacity for 
transmission and pathogenicity [13]. 
 
 
 
 
3 
 
HIV-1 genome and structure 
HIV-1 has a diameter of about 120nm [14]. Each virion contains two identical copies of 
single positive-stranded RNA genome, which is enclosed by nucleocapsid p6 and p7, 
matrix, reverse transcriptase and integrase, and envelope.  Nucleocapsids p7 and p6 
associate with the genomic RNA and protect the RNA from digestion by nucleases.  The 
capsid is surrounded with a matrix with viral protein p17, ensuring the integrity of the 
virion particle.  The envelope is formed when the capsid buds from the host cell, taking 
some of the host-cell membrane [15, 16]. The envelope glycoproteins gp120 and gp41 
form spikes on the virions and play important role in virus-cell attachment [17].  The 
RNA genome contains seven structural landmarks (LTR, TAR, RRE, PE, SLIP, CRS, and 
INS) and nine genes (gag, pol, and env, tat, rev, nef, vif, vpr, vpu, and tev) [18, 19].  The 
Tat protein is a transcriptional transactivator for 5’ long terminal repeats (LTR) promoter 
and functions by binding the trans-activation response element (TAR) RNA element.  The 
Rev protein functions to shuttle RNAs from the nucleus and the cytoplasm by binding to 
the Rev responsive element (RRE).  The Nef protein (p27) down-regulates CD4, as well 
as the MHC class I and class II molecules.  The Vpu protein (p16) regulates release of 
new virus particles from infected cells.  LTR promoter has three regions: U3, R, and U5, 
which contains all the signals for gene expression: enhancer, promoter, transcription 
initiation (capping), transcription terminator and polyadenylation signal.  The integrated 
provirus has two LTRs, and the 5' LTR normally acts as an RNA pol II promoter, while 3’ 
LTR works in transcriptional termination and polyadenylation. 
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HIV-1 life cycle 
HIV enters its target cells through interaction of viral glycoprotein spikes with CD4 and 
chemokine receptor CCR5 or CXCR4 on the cell surface.  CCR5 is used by non-
syncytium-inducing（NSI）macrophage-tropic HIV-1 isolates at the early stage of HIV-
1 infection, while CXCR4 is used by syncytium-inducing (SI) strain T cell-tropic HIV-1 
isolates at later stages of HIV-1 infection [20-22].  Then, the viral envelope is fused with 
the cell membrane; the virion core including RNA genome, capsid, and viral enzymes is 
released into the cell.  After the virion core enters the cell, reverse transcriptase converts 
single-stranded viral RNA into proviral DNA.  This process often gives rise to mutations 
that offer drug-resistance or allow the virus to evade the body's immune system because 
of the highly error-prone nature of reverse transcriptase.  Proviral DNA is then imported 
into the nucleus and becomes integrated into host genome by viral integrase [23, 24].  
Viral RNA are transcribed from the integrated proviral DNA and exported into cytoplasm 
for viral protein synthesis [25, 26].  The final step of the viral cycle is assembly of new 
HIV-1 virons, which occurs at the plasma membrane of the host cells.  During the 
maturation of virons, HIV protease cleaves the polyproteins into individual functional 
HIV structural proteins and enzymes and the virus becomes mature and ready for the new 
round of infection [27].   
 
 
 
 
 
5 
 
Anti-HIV therapy  
The anti-HIV therapeutic strategy has been mainly targeted at RT and PR.  Some 
advances have been recently made to target the viral entry and IN.  RT inhibitors block 
the virus from synthesizing DNA from its RNA; PR inhibitors block cleavage of HIV 
polyproteins into individual viral structural proteins during virus maturation; fusion 
inhibitors, the new class of drugs, block viral envelope fusion with cell membrane; IN 
inhibitors prevent proviral DNA from being integrated into host chromosome.  The Food 
and Drug Administration (FDA) of the United States of America has approved a total of 
21 anti-HIV-1 drugs, a majority of these drugs are HIV-1 RT and PR inhibitors [28].  
Enfuvirtide (Fuzeon) are the two approved HIV fusion inhibitors. Maraviroc binds to 
CCR5, preventing an interaction with gp120 [29], while Fuzeon binds to gp41 and 
interferes with its ability to approximate the two membranes [30]. 
 
The current treatment for HIV infection is called highly active antiretroviral therapy 
(HAART) and is a combination of these inhibitors above.  HAART is very effective in 
suppressing HIV-1 replication, but it cannot eradicate the virus from the infected subjects 
[31].  This therapy cannot achieve the consistent optimal results, because of the non-
adherence and non-persistence issues.  The reasons for non-adherence and non-
persistence could be both psychosocial issues and the complexity of these HAART 
regimens, such as poor access to medical care, inadequate social supports, and drug abuse; 
and dosing frequency, meal restrictions or other issues along with side effects. These 
limitations pose great challenges for long-term HIV/AIDS management [32].  Meanwhile, 
there have been no vaccines available for HIV/AIDS.  Therefore, continued efforts have 
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been putting into development of new and alternative therapeutic strategies with lower 
cost, fewer side-effects, and best regimens to manage drug resistance. 
 
 
Traditional Chinese medicine and its anti-HIV activity  
Traditional Chinese medicine (TCM) constitutes an important form of medical care for 
various human diseases in east Asian countries for many thousands of years, and Chinese 
herbs-based medication is the most important part of TCM [33].  Unlike one single 
compound-based Western medicine, TCM is a mix of multiple ingredients that are 
carefully balanced and standardized to maximize its therapeutic efficacy while minimize 
its toxicity and side-effects.  Currently, HIV-1-inhibitory TCMs are reported to include 
Scutellaria baicalensis Georgi, Prunella vulgaris, Paeonia Suffruticosa, Rhizoma 
Polygoni Cuspidati, Radix Notoginseng, Ramulus Visci, and Ajuga Decumbens Thumb 
[34-39].  Our studies added Euphorbiaceae, Trigonostema xyphophylloides (TXE) and 
Dipterocarpaceae, Vatica astrotricha (VAD) onto this soon-to-be-rapidly-expanding list.  
Studies are under way to further fractionate these extracts for identification of the active 
anti-HIV-1 entry constituents in these extracts and for better characterization of their 
effects on the interaction between HIV-1 gp120 and CD4/chomine receptors CCR5 and 
CXCR4 [40]. 
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Anti-HIV-1 activity of flavonoids (FL) compounds 
FL are also known as Vitamin P or citri, which belongs to the class of plant secondary 
metabolites.  FL are not only the major components in our daily nutrients, but also widely 
used in medications acting as antioxidants, enzyme inhibitors, and precursors of toxic 
substances.  These compounds possess anti-flammatory, antithrombotic, anticarcinogenic, 
and antiviral inculding anti-HIV-1 activities [41].  The anti-HIV-1 activity of FL 
compounds been implicated in the inhibition of RT enzyme [42].  Baicalin (BA, 7-
glucuronic acid,5,6-dihydroxyflavone) is purified from FL compound that also have 
known to possess anti-inflammatory and anti-HIV-1 activities through strengthening host 
defense.  Instead of inhibiting the RT enzymatic activity, BA has been found to inhibit 
HIV-1 infection of human peripheral blood mononuclear cells by interfering with viral 
entry, through the interaction between HIV-1 envelope proteins and the cellular CD4 and 
chemokine receptors (both CD4/CXCR4 or CD4/CCR5) [43].  
 
 
The goals of the current study 
In a previous study, we show that extracts from two Chinese medicinal herbal plants in 
Hainan Island, China Euphorbiaceae, Trigonostema xyphophylloides (TXE) and 
Dipterocarpaceae, Vatica astrotricha (VAD) both block HIV-1 replication at the entry 
[40].  In the current study, we continued to screen and characterize nine more extracts 
from Chinese medicinal herbal plants or their parts: leaves, stems and roots of 
Annonaceae Artabotrys pilosus (AAP), Annonaceae Oncodostigma hainanense (AOH) 
and Annonaceae Dasymaschalon rostratum (ADR) for their anti-HIV activities.  These 
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extracts have been used as TCM to treat malaria, cancers and bacterial and fungal 
infections, stop bleeding, repair fractures, and ameliorate bruises [44].  Several chemical 
compounds have been isolated and identified from the plant extracts of the Annonaceae 
family and include flavonoids (FL), alkaloids (AL) and acetogenins (AT) [45].  
9 
 
METHODS AND MATERIALS 
Preparation of plant extracts  
All plants used in this study were collected at the tropical national forest park 
Bawangling, Hainan Island, P. R. China (Table 1).  Scientific names and classification of 
these plants were validated by Prof. Chen of Hainan Normal University, Haikou, P. R. 
China.  Samples of these plants were kept at the Hainan Provincial Key Laboratory of 
Tropical Pharmaceutical Herbal Chemistry, Haikou, P. R. China.  Plant samples were air 
dried, grinded and continued to be dried in a pressurized oven at 40°C and 0.08 MPa.  
The dried and grinded materials were then subjected to three rounds of refluxing 
extraction in 75% ethanol at 80°C.  The ethanol extracts were then concentrated to 
become ointment in a revolving depressurized vacuum evaporator at 55°C.  The ointment 
was further lyophilized to the final form of powder and stored at desiccators.  The 
powders were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 100 mg/ml 
and kept as stock at -20°C.   
 
 
Cells, HIV-1 HXB2/YU-2 viruses and chemicals 
Jurkat cells and CEM-GFP cells stably expressing HIV-1 long terminal repeat promoter-
driven green fluorescence protein (GFP) were cultured in RPMI-1640 medium (Lonza, 
Wwalkersville, MO) supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO) 
and 100 units/ml penicillin (Sigma).  G418 (Lonza)(1.25 mg/ml) was included in medium 
for CEM-GFP cells.  U87.CD4.CXCR4 and U87.CD4.CCR5 cells stably expressing 
CD4/CXCR4 and CD4/CCR5 respectively were obtained from the NIH AIDS Reagent 
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Program and cultured in DMEM (Lonza) supplemented with 10% fetal bovine serum and 
100 units/ml penicillin.   
 
 
Preparation and infection of HIV-1 pseudotyped viruses 
293T cells were plated in a 10 cm dish at a density of 2 x10
6
 cells per plate and 
transfected with 20 μg HIV-Luc plasmid and 4 μg pHXB2-env, pYu2-env, pVSV-G, or 
pcDNA3 [40] by the calcium phosphate precipitation method.  After 48 hr incubation, the 
cell culture supernatant was collected, cleared of cell debris, and used for infection.  The 
virus titers were determined by reverse transcriptase assay [46] and expressed as counts 
per min per milliliter (cpm/ml).  For infection, pseudotyped viruses corresponding to a 
2,000 cpm RT activity were used to infect target cells.  After 2 hr infection, the culture 
medium was replaced with the fresh DMEM, continued to incubate for 48 hr and 
harvested for the Luc activity assay [47, 48]. 
 
 
Reverse transcriptase (RT) assay 
The RT activity assay was used to quantitate the relative virus titers and was performed 
as follows.  Briefly, cell culture supernatants were collected, cleared of cell debris by a 
brief centrifugation, followed by centrifugation at 10,000 g at 4°C for 1 hr to obtain the 
virion pellet.  The virion pellet was suspended in 10 l dissociation buffer [30 mM Tris 
HCl, pH 8.1, 0.1M KCl, 6 mM dithiothreitol (DTT) and 0.6% Triton X-100], followed by 
three rounds of freezing and thawing.  Then, 40 l reaction mixture containing 34 l 
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reaction buffer (50 mM Tris HCl, pH 8.0, 2 mM DTT, 100 mM KCl, 10 mM MgC12, 
0.01% Triton X-100), 5 l template primer poly(A):oligo(dT) (Roche, Indianapolis, IN) 
and 1 l 3H-thymidine (PerkinElmer, Boston, MA) was added to each sample.  After one 
hour incubation under 37°C, each sample was spotted onto Whatman DE81 filter disc 
and let air dried at room temperature.  This was followed by three times of washes with 
2x SSC (0.3 M NaCl and 0.03M sodium citrate) and two times of washes with 100% 
ethanol. The radioactivity on the filter disc was measured in a liquid scintillation counter 
and used to express as the relative RT activity  [49]. 
 
 
HIV replication assay 
One million Jurkat cells were infected with HIV-1 corresponding to a 10,000 cpm RT 
activity in a total volume of 1 ml.  Twenty-four hours post-infection, cells were treated 
with plant extracts at indicated concentrations or an equivalent concentration of the 
DMSO solvent.  The culture supernatants were collected for the RT activity assay every 
other day, while fresh extracts or DMSO was replenished. 
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Cytotoxicity assay 
The cytotoxicity of these extracts was determined by using the trypan blue exclusion 
method.  Briefly, aliquots of HIV-infected and extracts-treated Jurkat cells were collected 
every other day, stained in 0.2% trypan blue dye, then counted for viable cells under a 
light microscope.  Uninfected and HIV-infected and DMSO-treated Jurkat cells were 
included as controls. 
 
 
Flow cytometry analysis  
CEM-GFP cells were treated with 10 g/ml each of the extracts for 3 days or 7 days, and 
then harvested to determine the GFP expression by flow cytometry. 
 
 
Data analysis 
Results are expressed as mean ± SEM.  The statistical significance of the differences 
between the means of the experimental groups was tested by two-tailed student’s t-test.  A 
difference was considered as significant when p is < 0.05, and highly significant when p 
is < 0.01. 
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RESULTS 
The purpose of these experiments was to determine whether any of nine selected 
traditional Chinese medicinal herbal extracts from Annonaceae family have anti-HIV 
activity and at which steps of the HIV viral cycle they inhibit HIV-1 replication including 
entry, reverse transcription, gene expression, and post-entry.  Different dosages were also 
evaluated for the anti-HIV effects of the extracts. 
  
 
Anti-HIV activity of the extracts of traditional Chinese medicinal herbal plants  
To determine whether any of the nine selected extracts (Table 1) have anti-HIV activity, 
we infected CD4+ T lymphocytes Jurkat cells with a replication-competent T-tropic HIV-
1 strain HXB2, and then treated the cells with these extracts at concentrations of 10 
g/ml or 100 g/ml for 2 weeks.  DMSO was included as a vehicle control. Mock-
infected Jurkat cells and HIV-infected cells without any treatments were also included as 
controls.  The results showed that compared to DMSO control sample, there were low 
HIV-1 replications in cells that were treated with 10 g/ml extracts from the leaves, stems 
and roots of Annonaceae, Artabotrys pilosus (AAP-leaves, stems, and roots) and from the 
roots of Annonaceae Dasymaschalon rostratum (ADR-roots) (Fig. 1).  However, in the 
rest of five extracts, we did not detect the significant block in HIV-1 replication (Table 2). 
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Cytotoxicity of the extracts 
Throughout the infection experiments (Fig. 1), we also monitored cell survival of cells of 
all treatments by trypan blue dye staining.  The results showed that at the concentration of 
10 g/ml the cell viability in all extract treatments was similar to that in mock or DMSO-
treated cells (Fig. 2).  Nevertheless, at a concentration of 100 g/ml, the cell viability in 
all DMSO-treated and extracts-treated cells began to decrease at day 5 (data not shown).  
Based on these results, the extract concentration of 10 μg/ml was chosen for all following 
mechanistic studies. 
 
 
Dose-dependent inhibition of HIV-1 replication by these extracts 
We further determined whether the inhibitory effects on HIV-1 replication of these 
extracts were dose-dependent.  We infected Jurkat cells with HIV-1 viruses and then 
treated the cells with each of the extracts at a concentration of 5 g/ml or 1 g/ml.  Fresh 
extracts were added every other day, while the supernatants were collected for the RT 
activity assay. At the concentration of 1 g/ml, compared to controls, none of the extracts 
showed significant inhibition of HIV-1 replication, while at the concentration of 5 g/ml, 
these extracts showed to a different extent inhibitory or delayed effects on HIV-1 
replication (Fig. 3).  At both 1 and 5 g/ml concentrations, extracts showed little effects 
on cell viability (data not shown).  These results suggest a dose-dependent inhibition of 
HIV-1 replication by these extracts and also support our choice of the 10 g/ml 
concentration of these extracts throughout our studies.   
 
15 
 
Block of HIV-1 entry by these extracts 
HIV-1 infection begins with HIV-1 envelope gp120 binding to CD4 and chemokine 
coreceptors CCR5 for M-tropic HIV-1 stains or CXCR4 for T-tropic HIV-1 strains.  We 
then determined whether these extracts had any inhibitory effects at the viral entry step. 
We took advantage of the replication-defective single round HIV-Luc reporter system 
[50].  In this reporter system, HIV-1 env gene is nonfunctional and the firefly luciferase 
gene is inserted into and inactivates HIV-1 nef.  The reporter virus system allows in trans 
complementation of env genes to not only study HIV-1 tropism, but also accurately 
monitor HIV-1 entry.  To this end, we transfected HIV-Luc reporter and T-tropic HIV-1 
HXB2 or M-tropic HIV-1 YU-2 envelope DNA and obtained HXB2 or YU-2 envelope-
pseudotyped HIV-Luc viruses. We then pre-treated U87.CD4.CXCR4 or U87.CD4.CCR5 
cells for 1 hour with 10 g/ml each of extracts before we infected these cells with the 
pseudotyped viruses (HXB2 for U87.CD4.CXCR4; YU-2 for U87.CD4.CXCR5).  We 
also included pseudotyped viruses without any envelope and vascular stomatitis virus 
envelope glycoprotein (VSV-G)-pseudotyped viruses as negative and positive controls, 
respectively.  Compared to the DMSO treatment, all extract treatments showed little 
luciferase activity in HXB2-infceted U87.CD4.CXCR4 cells (Fig. 4A) or YU-2-infceted 
U87.CD4.CCR5 cells (Fig. 4B), suggesting that pre-treatment of these extracts 
completely blocked entry and infection of both T- and M-tropic HIV viruses.  These 
extracts showed little effects on entry of VSV-G-pseudotyped viruses, while HIV-Luc 
pseudotyped without any envelopes had no luciferase assay readings (data not shown).  
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No effects of the extracts on HIV-1 infectivity 
To further confirm that these extracts inhibited HIV-1 replication through masking the 
receptors on the target cells during the entry step, we determined if these extracts have 
effects on HIV-1 infectivity.  To this end, we incubated HXB2- or YU-2-pseudotyped 
HIV-Luc viruses with the extracts 37°C for 2 hr.  We then recovered the viruses by 
centrifugation.  We then infected U87.CD4.CXCR4 or U87.CD4.CCR5 cells with these 
viruses.  Compared to DMSO treatment, these extract treatments showed little differences 
of the luciferase activity (Fig. 5), further indicating that these extracts have no effects on 
HIV-1 itself. 
 
 
No effects of the extracts on HIV-1 post-entry 
To determine whether these extracts had inhibitory effects on any post-entry events, we 
first infected U87.CD4.CXCR4 with HXB2-pseudotyped HIV-Luc or U87.CD4.CCR5 
cells with YU-2-pseudotyped HIV-Luc, washed off the unbound viruses, and then treated 
the cells with the extracts.  Compared to DMSO treatment, none of the extract-treated 
cells showed significant decreases in the luciferase activity (Fig. 6), suggesting that these 
extracts have no effects on any post-entry events and further confirming that these 
extracts inhibit HIV-1 replication at the entry step of the viral life cycle. 
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Inhibition of HIV-1 RT activity by extract of AAP-leaves and AAP-stems 
Reverse transcriptase (RT) is absolutely required for the HIV-1 life cycle, as it converts 
the single-stranded RNA genome to a cDNA molecule.  Thus, we next determined 
whether these extracts have any direct inhibitory effects in HIV-1 RT enzymatic activity.  
To this end, we purified the HIV-1 virions, lyzed them to release the RT, and them 
determined the RT activity in the presence of the extracts.  We also included 0.1% DMSO 
as a vehicle control and AZT as a positive control in these experiments.  Compared to 
AZT treatment, extracts of AAP-leaves and AAP-stems but not AAP-roots and ADR-
roots significantly inhibited HIV-1 RT enzymatic activity (Fig. 7).  
 
 
No inhibition of HIV-1 LTR promoter activity by the extracts 
The HIV-1 long terminal repeat (LTR) promoter controls HIV-1 gene transcription and is 
an important regulatory step of HIV-1 gene expression.  Thus, we first determined 
whether these extracts affect the HIV-1 LTR promoter activity.  We took advantage of the 
CEM-GFP cells in which the green fluorescence protein (GFP) is under the control of the 
HIV-1 LTR promoter [51]. We treated these cells with 10 g/ml of each extract for 3 days 
or 7 days and determined the relative GFP expression level. We treated the cells with 
extracts for 7 days to ensure complete GFP turnover.  The results showed no significant 
difference of GFP intensity between each of the extracts and the DMSO control (Fig. 8), 
suggesting that the extracts from AAP-leaves, AAP-stems, AAP-roots and ADR-roots 
have no inhibitory effects on HIV-1 LTR promoter activity and gene transcription. 
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DISCUSSIONS 
In this study, we modified the HIV-1 replication system, a well-established system 
published in our previous work to screen nine new TCM herbal extracts from Hainan 
Island, China to determine their anti-HIV-1 effects (Table 1). These extracts are from 
leaves, stems and roots of three different Chinese medicinal herbal plants from 
Annonaceae family – AAP, AOH and ADR. Annonaceae family, which consists of 2300 
to 2500 species and more than 130 genera, their stems, leaves and roots of some species 
are used as Chinese traditional medicine. These species are well-known working in 
antifungal, bacteriostatic, antimalarial, and cytostatic capability of some chemical 
constituents of the leaves and stems. The chemical compounds, including flavonoids(FL), 
alkaloids(AL) and acetogenins(AT), have been extracted [45]. Baicalin (BA) is purified 
from FL compound that have known to possess anti-inflammatory and anti-HIV-1 
activities. BA inhibits HIV-1 infection by interfering with viral entry, through the 
interaction between HIV-1 envelope proteins and the cellular CD4 and chemokine 
receptors (both CD4/CXCR4 and CD4/CCR5) [43, 52, 53]. 
 
We found that AAP-leaves, AAP-stems, AAP-roots and ADR-roots have completely 
blocked HIV-1 replication at concentration of 10  (Fig. 1 and Fig. 2). Instead, we 
did not see any significant HIV-1 replication inhibitions in the rest of other samples (data 
shown as percentages in Table 2). Dosage experiments were included to detect whether 
the different would affect anti-HIV. The data indicated that the extracts have no 
inhibitions on HIV-1 replication at concentration of 1 g/ml, while at concentration of 5 
g/ml, AAP—leaves and AAP-roots treated cells showed significant inhibition compared 
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to DMSO-treated cells on HIV-1 replication (Fig. 3). Following this results, we detected 
the mechanisms of these extracts by testing direct effects on LTR promoter activities, RT 
enzymatic activities and HIV-1 virus entry. However, we did not detect any effects of 
these extracts on LTR promoter activities (Fig. 8). On other hand, we showed the 
significant inhibition of HIV-1 RT enzymatic activities by treating RT with AAP-leaves 
and AAP-roots directly (Fig. 7). Moreover, we also determined that all four sample 
potently blocked HIV-1 from entering its target cells (Fig. 4). Shortly, these results 
indicated that four samples have anti-HIV infection: AAP-stems and ADR-roots block 
HIV-1 replication through interfering with HIV-1 entry, while AAP-leaves and AAP-roots 
block HIV-1 replication by both interfering with HIV-1 RT enzymatic activities and their 
entry. To further boost this conclusion, we performed the experiments of HIV-1 
infectivity and post-entry. However, there were no effects of these extracts on both HIV-1 
infectivity and post-entry (Fig. 5 and Fig. 6). 
   
Theoretically, corresponding to the HIV-1 virion cycle, the extracts should have 
inhibitions to HIV-1 post-entry when they block RT enzymatic activity. However, from 
the results, AAP-leaves and AAP-roots had statistically inhibitions on RT enzymatic 
activity, while neither of them had effects on HIV-1 post-entry (Fig. 6 and Fig. 7). This 
could be because the extracts were not able to enter the U87.CD4.CCR5/CXCR4 cells, 
but interfere with the virion entry. This could also be one possible explanation on LTR 
promoter experiment that the extracts were not capable entering CEM-GFP cells. (Fig. 8) 
Taken all together, AAP-leaves, AAP-stems, AAP-roots and ADR-roots have completely 
blocked HIV-1 replication at concentration of 10 g/ml, while AAP-leaves and AAP-
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roots delayed HIV-1 replication at concentration of 5 g/ml. These four extracts achieved 
this conclusion by interfering with HIV-1 entry step. Further studies are required to 
indicate whether they inhibited both T cell tropic (X4) and monocyte tropic (R5) HIV-1 
Env protein mediated fusion with cells expressing CD4/CXCR4 or CD4/CCR5, or inhibit 
binding of HIV-1 gp120 to CD4, even though flavonoid baicalin interfere with the 
interaction of HIV-1 Env and chemokines. Furthermore, AAP-leaves and AAP-roots can 
also inhibit HIV-1 RT enzymatic activities. These results are also consistent with the 
previous data that chemical compound FL inhibits HIV-1 infection at the level of viral 
entry and RT enzymatic activity [43]. 
 
The goal of anti-HIV medication treatment is to reduce the amount of virus in a person's 
body and prevent destruction of the immune system. They help HIV/AIDS infected 
patients live a longer life.  There are twenty-one anti-HIV medications currently in 
market approved by the U.S. Food and Drug Administration (FDA) for the treatment of 
HIV. HIV patients are required to use these medications in combination. However, all the 
antiretroviral drugs have different levels negative side effects, from mild to life-
threatening [32]. In contract, traditional Chinese medicinal herbal extracts have a much 
short development cycle, much fewer side-effects and relatively inexpensive due to their 
natural origin.  
 
With the history of 2000-3000 years, TCM cure several illnesses by their unique system.  
The basic TMC treatment principle with HIV/AIDS is to support the body's energetic 
basis by nourishing the deficiencies while eliminating the deeper underlying pathogens 
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such as Toxic Heat, Phlegm, and Blood Stasis [8]. There are a few of Chinese herbs using 
for treating HIV/AIDS patients: Immunity-boosting herbs, such as astragalus, echinacea, 
and ginkgo are also used to help revive an ailing immune system, and certain herbs such 
as garlic are used to battle bacteria and viruses in HIV/AIDS treatments. 
Deglycyrrhizinated licorice can soothe the mouth and throat ulcers that often accompany 
full-blown AIDS. In this study, I detected another four possible samples from 
Annonaceae Family: AAP-leaves, AAP-stems, AAP-roots and ADR-roots, to inhibit HIV-
1 replication through interrupting HIV-1 replication entry. However, to develop new 
drugs and improved formulations from Chinese herbs, many challenges applied due to 
their lack of active ingredient [54]. 
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TABLES 
 
NO. Plant (family, species) 
Sampling 
location 
Sampling 
parts 
Medicinal 
usage 
1 Annonaceae, Artabotrys pilosus Merr. et Chun Bawangling Leaves 
Anti-Malaria, 
TB 
2 Annonaceae, Artabotrys pilosus Merr. et Chun Bawangling Stems 
Anti-Malaria, 
TB 
3 Annonaceae, Artabotrys pilosus Merr. et Chun Bawangling Roots 
Anti-Malaria, 
TB 
4 
Annonaceae, Oncodostigma 
hainanense(Merr.) Tsiang et P.T.Li 
Bawangling Fruit 
Bleeding, 
fractures, 
bruises 
5 
Annonaceae, Oncodostigma 
hainanense(Merr.) Tsiang et P.T.Li 
Bawangling Leaves 
Bleeding, 
fractures, 
bruises 
6 
Annonaceae, Oncodostigma 
hainanense(Merr.) Tsiang et P.T.Li 
Bawangling Stems 
Bleeding, 
fractures, 
bruises 
7 
Annonaceae, Dasymaschalon rostratum Merr. 
et Chun 
Bawangling Roots Anti-tumor 
8 
Annonaceae, Dasymaschalon rostratum Merr. 
et Chun 
Bawangling Stems Anti-tumor 
9 
Annonaceae, Dasymaschalon rostratum Merr. 
et Chun 
Bawangling Leaves Anti-tumor 
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Table 1. The information of the nine Chinese herbal medicinal extracts. These 
extracts are from Annonaceae family, found in national tropical forest parks in Hainan 
island Bawangling, P. R. China. Plant samples were first air dried, grinded and continued 
to be dried in a pressurized oven at 40°C and 0.08 MPa. The dried and grinded materials 
were subjected to three rounds of refluxing extraction in 75% ethanol at 80°C. The 
ethanol extracts were then concentrated to become ointment in a revolving depressurized 
vacuum evaporator at 55°C. The ointment was further lyophilized to the final form of 
powder and stored at a desiccator. 
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samples/dates Day 4 Day 6 Day 8 Day 10 Inhibit HIV 
replication? 
DMSO 3±0.3 12±2.7 56±8.8 100  
AAP-leaves 0.62±0.1 2.2±1.2 2.0±0.7 2.5±1.5 Yes 
AAP-stems 0.68±0.3 0.8±0.2 2.9±0.8 2.8±0.1 Yes 
AAP-roots 0.52±0.31 0.48± 
0.01 
2.5±0.9 1.4±0.2 Yes 
AOH-fruit 5.12±1.1 86.8± 8.3 121±23 178±12 No 
AOH-stems 5.0±0.06 67±6 102±32 94±8 No 
AOH-leaves 0.4±0.01 19±3.2 77±33 75±21 No 
ADR-leaves 2.1±0.3 63±0.5 115±7.4 107±10  No 
ADR-stems 2.4±0.3 71±4.6 79±18 122±8 No 
ADR-roots 0.17±0.04 0.6±0.5 2.6±1.3 2.3±0.7 Yes 
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Table 2. The average percentage of HIV-1 replication with nine extracts treatments 
based on three independent experiments. The RT assay readings of each sample were 
collected every other day. The percentage was considered as 100% when HIV-1 
replication of DMSO sample reached to the peak. Instead, the rest of other samples with 
extracts treatments were calculated and converted into percentages based on DMSO. The 
data were mean ± SEM of three independent experiments.  
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Figure 1. Effects of extracts on HIV-1 replication. One million Jurkat cells were 
infected with HIV-1 HXB2 corresponding to a 10,000 cpm RT activity for 24 hr and then 
treated with 10 g/ml fresh extracts from the leaves, stems and roots of Annonaceae, 
Artabotrys pilosus (ARP-leaves, stems, and roots) and the roots of Annonaceae, 
Dasymaschalon rostratum (ADR-roots) every other day.  The cell culture supernatants 
were collected at indicated time points for the RT activity assay. All extracts were 
dissolved in DMSO, and DMSO was used as a vehicle control. Mock-infected Jurkat 
cells and HIV-infected cells without any treatments were also included as controls.  These 
data were representative of three independent experiments. 
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Figure 2. Effects of extracts on Jurkat cell survival.  Jurkat cells were infected and 
treated as in Fig. 1.  At each time point, aliquot of cells was collected, stained with trypan 
blue dye, and then counted for the cell viability.  These data were representative of three 
independent experiments. 
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A. 
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Figure 3. Effects of extracts on HIV-1 replication at different doses. Jurkat cells were 
infected as in Fig. 1. Then the cells were treated with 5 g/ml (A) or 1 g/ml (B) fresh 
extracts from AAP-leaves, stems, and roots and ADR-roots every other day. RT assay was 
applied as in Fig.1. DMSO was used as a vehicle control and mock-infected cells was 
included as a negative control. These data were representative of three independent 
experiments. 
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Figure 4. Effects of extracts on HIV-1 entry.  A. U87.CD4.CXCR4 cells were treated 
with 10 g/ml each of the extracts for 1 hr and then infected with HIV-Luc viruses 
pseudotyped T-tropic HIV-1 HXB2 envelope.  B. Similar experiments were performed 
with U87.CD4.CCR5 cells and HIV-Luc viruses pseudotyped M-tropic HIV-1 YU-2 
envelope.  HIV-Luc viruses pseudotyped with VSV-G envelope and no envelope were 
included as the positive and negative infection controls, respectively (data not shown).  
The data were mean ± SEM of triplicate experiments. 
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Figure 5. Effects of extracts on HIV-1 infectivity.  HIV-Luc virus pseudotyped with 
HXB2 (A) or YU-2 envelope (B) was first incubated with 10 g/ml each of the extracts at 
37°C for 2 hr.  The virus was recovered by centrifugation and then used to infect either 
U87.CD4.CXCR4 (for HXB2) or U87.CD4.CCR5 cells (for YU-2).  The cells were 
harvested for the luciferase reporter gene assay 48 hr post infection.  The data were mean 
± SEM of triplicate experiments.  
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Figure 6. Effects of extracts on HIV-1 post-entry.  U87.CD4.CXCR4 and 
U87.CD4.CCR5 cells were first infected with HIV-Luc virus pseudotyped with HXB (A) 
or YU-2 envelope (B).  Following medium change, the cells were treated with 10 g/ml 
each of the extracts for 48 hr and then harvested for the luciferase reporter gene assay.  
The data were mean ± SEM of triplicate experiments.  
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Figure 7. Effects of extracts on the HIV-1 RT activity.  Purified HIV-1 virions were 
incubated with 10 g/ml each of the extracts for the RT activity assay.  The RT inhibitor 
AZT (5 μM) was included as a positive control, while DMSO was used as the vehicle 
control for the extracts.   
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Figure 8. Effects of extracts on the HIV-1 long terminal repeat (LTR) promoter 
activity.  CD4+ T lymphocytes CEM stably expressing green fluorescence protein (GFP) 
under the control of HIV-1 LTR promoter were treated with 10 g/ml each of the extracts 
for 3 days (A) and 7 days (B).  Then, the cells were collected for GFP expression by flow 
cytometry.  The data were the geometric means of the GFP expression level and were 
mean ± SEM of triplicate experiments. 
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